2DT Stoklara Genel Bakış Amneal Pharmaceuticals, Inc. iştirakleri ile birlikte jenerik, enjektabl, biyobenzer ve özel markalı farmasötik ürünler geliştirmekte, üretmekte, pazarlamakta ve dünya çapında dağıtımını yapmaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Amneal Pharmaceuticals, Inc. Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Amneal Pharmaceuticals Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$7.40 52 Haftanın En Yüksek Seviyesi US$8.55 52 Haftanın En Düşük Seviyesi US$4.74 Beta 1.1 1 Aylık Değişim 1.37% 3 Aylık Değişim -7.50% 1 Yıllık Değişim 48.59% 3 Yıllık Değişim 89.74% 5 Yıllık Değişim 56.78% Halka arzdan bu yana değişim -59.80%
Son Haberler & Güncellemeler
Insufficient new directors Dec 30
Amneal Pharmaceuticals, Inc. Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist Nov 22
Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023) Nov 10
Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024 Nov 08
New major risk - Shareholder dilution Nov 08
Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 09 Daha fazla güncelleme görün
Insufficient new directors Dec 30
Amneal Pharmaceuticals, Inc. Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist Nov 22
Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023) Nov 10
Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024 Nov 08
New major risk - Shareholder dilution Nov 08
Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 09
Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials Aug 20
Insider recently sold €703k worth of stock Aug 18
Second quarter 2024 earnings released: EPS: US$0.019 (vs US$0.078 in 2Q 2023) Aug 11
Amneal Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2024 Aug 09
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules Aug 08
Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags Jul 30
Amneal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024 Jul 12
Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant Jul 10
Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar Jul 03
Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies Jun 06
Independent Director recently sold €236k worth of stock May 21
First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023) May 04
Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose Apr 25
Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA) Apr 19
Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024 Apr 11
Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024 Mar 23
Full year 2023 earnings released: US$0.48 loss per share (vs US$0.86 loss in FY 2022) Mar 04
Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024 Mar 01
Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024 Feb 01 Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension
Third quarter 2023 earnings released: EPS: US$0.063 (vs US$0.018 loss in 3Q 2022) Nov 09 Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023 Oct 24
Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 06 Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection
Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease Aug 25
Second quarter 2023 earnings released: EPS: US$0.078 (vs US$0.80 loss in 2Q 2022) Aug 06
Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023 Aug 05
Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics Jul 27
Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023 Jul 07
Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter Jul 04
Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable Jun 15
Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States May 17
First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022) May 10
Insufficient new directors May 10
First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022) May 07
Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023 May 06
Full year 2022 earnings released: US$0.86 loss per share (vs US$0.071 profit in FY 2021) Mar 04
Amneal Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 02, 2023 Feb 01
Insufficient new directors Jan 20
Insufficient new directors Jan 01
Amneal Pharmaceuticals, Inc. Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval Dec 21
Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States Nov 23
Amneal Pharmaceuticals, Inc. Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease Nov 12
Third quarter 2022 earnings released: US$0.018 loss per share (vs US$0.028 loss in 3Q 2021) Nov 05 Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2022
Amneal Pharmaceuticals, Inc. Receives FDA Approval for Leuprolide Acetate Injection Nov 03
Amneal Pharmaceuticals, Inc. Announces Management Changes Nov 01
Amneal Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 04, 2022 Oct 07
Amneal Pharmaceuticals, Inc. Announces the Commercial Launch of ALYMSYS Oct 04
Amneal Pharmaceuticals, Inc. Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty Sep 07
Amneal Pharmaceuticals, Inc. Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease Sep 01
Amneal Pharmaceuticals, Inc. Launches 4 New Generic Products, Including Vasopressin Single-Dose Aug 12
Second quarter 2022 earnings released: US$0.80 loss per share (vs US$0.098 profit in 2Q 2021) Aug 06
Amneal Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2022 Aug 06
High number of new directors Aug 04
Amneal Pharmaceuticals, Inc. Appoints Deborah M. Autor to Board of Directors Aug 04
Amneal Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 05, 2022 Jul 09
Amneal Pharmaceuticals, Inc. Announces Class Action Lawsuit Settlement Updates Jun 07
Amneal Pharmaceuticals, Inc. Launches LYVISPAH for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders Jun 03
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk) May 28
First quarter 2022 earnings released: US$0.014 loss per share (vs US$0.045 profit in 1Q 2021) May 05
Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022 May 05
Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly) Apr 14
Amneal Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 08 Amneal Pharmaceuticals, Inc. Reports Asset Impairment Charges for the Three Months Ended December 31, 2021
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 03
Amneal Pharmaceuticals, Inc. Receives Approval of Releukotm Mar 03
Amneal Pharmaceuticals, Inc. Expands Injectables Portfolio with 4 New Products Feb 18
Amneal Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 02, 2022 Feb 05
Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2021 Jan 12
Co-Founder recently bought €553k worth of stock Dec 18
Co-Founder recently bought €553k worth of stock Dec 18
Amneal Pharmaceuticals, Inc. Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations Aug 26
Second quarter 2021 earnings released: EPS US$0.098 (vs US$0.081 loss in 2Q 2020) Aug 10
Amneal Pharmaceuticals, Inc. Receives Approval for Generic TobraDex Jul 20
Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab Jun 18
Amneal Pharmaceuticals, Inc Announces That the Food and Drug Administration Recently Accepted Amneal’s 505(B)(2) New Drug Application for A Newly Licensed Dihydroergotamine Jun 08 Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended March 31, 2021
First quarter 2021 earnings released: EPS US$0.045 (vs US$0.78 in 1Q 2020) May 08
New 90-day high: €5.04 Mar 13
Investor sentiment improved over the past week Mar 11
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) acquired a sterile injectables manufacturing facility of Igenius Life Science LLP for approximately $8.1 million. Mar 10
Full year 2020 earnings released: EPS US$0.62 (vs US$2.74 loss in FY 2019) Feb 28
Revenue beats expectations Feb 28
Amneal Pharmaceuticals, Inc. Receives Approval for Generic Version of Ortho Evra® Feb 27 Hissedar Getirileri 2DT DE Pharmaceuticals DE Pazar 7D -3.3% -2.4% -0.7% 1Y 48.6% -16.3% 10.1%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 2DT geçen yıl % -16.3 oranında getiri sağlayan German Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: 2DT geçen yıl % 10.1 oranında getiri sağlayan German Piyasasını aştı.
Fiyat Oynaklığı Is 2DT's price volatile compared to industry and market? 2DT volatility 2DT Average Weekly Movement 5.9% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: 2DT son 3 ayda German piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: 2DT 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında Kuruldu Çalışanlar CEO Web sitesi 2002 7,850 Chirag Patel amneal.com
Amneal Pharmaceuticals, Inc. bağlı ortaklıkları ile birlikte jenerik, enjekte edilebilir, biyobenzer ve özel markalı farmasötik ürünler geliştirmekte, üretmekte, pazarlamakta ve dünya çapında dağıtımını yapmaktadır. Şirket üç segmentte faaliyet göstermektedir: Jenerik, Özel ve AvKARE. Jenerik segmenti, anında ve uzatılmış salımlı oral katı, toz, sıvı, steril enjekte edilebilir, burun spreyi, inhalasyon ve solunum, biyobenzer, oftalmik, film, transdermal yama ve topikal ürünler sunmaktadır.
Daha fazla göster Amneal Pharmaceuticals, Inc. Temel Bilgiler Özeti Amneal Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 2DT temel i̇stati̇sti̇kler Piyasa değeri €2.36b Kazançlar(TTM ) -€179.01m Gelir(TTM ) €2.60b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 2DT gelir tablosu (TTM ) Gelir US$2.68b Gelir Maliyeti US$1.70b Brüt Kâr US$979.05m Diğer Giderler US$1.16b Kazançlar -US$184.45m
Son Raporlanan Kazançlar
Sep 30, 2024
Hisse başına kazanç (EPS) -0.60 Brüt Marj 36.53% Net Kâr Marjı -6.88% Borç/Özkaynak Oranı -7,524.6%
2DT uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/01/15 13:36 Gün Sonu Hisse Fiyatı 2025/01/14 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Amneal Pharmaceuticals, Inc. 20 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Balaji Prasad Barclays Balaji Prasad Barclays Gary Nachman BMO Capital Markets Equity Research
Göster 17 daha fazla analist 
